Journal
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
Volume 47, Issue 2, Pages 117-128Publisher
WILEY
DOI: 10.1111/eci.12708
Keywords
Atherosclerosis; Mas receptor; neutrophils
Funding
- grant fellow of CAPES Foundation
- Ministry of Education of Brazil
- Swiss National Science Foundation Grant [310030_152639/1]
- Swiss National Science Foundation (SNF) [310030_152639] Funding Source: Swiss National Science Foundation (SNF)
Ask authors/readers for more resources
Background Neutrophil-mediated inflammation was recently identified as an active contributor to athero-progression. Therapeutic strategies inhibiting neutrophil degranulation or recruitment were hypothesized to positively impact on plaque vulnerability. In this study, we investigated whether treatment with the recently discovered agonist of the Mas-related G-coupled receptor type D (MrgD) alamandine would impact on neutrophil degranulation in vivo and in vitro. Materials and methods Fifteen-week-old ApoE(-/-) mice were fed with a Western-type diet for an additional 11 weeks. After the first 2 weeks of diet, mice were surgically implanted with a carotid 'cast' device that alters the blood shear stress and induces different carotid plaque phenotypes. During the last 4 weeks before euthanasia, mice were randomly assigned to subcutaneously receive vehicle (NaCl 0.15 M) or alamandine (24 lg/kg/h) by micropump. For in vitro experiments, neutrophils were obtained after thioglycollate intraperitoneal injection in ApoE(-/-) mice. Results Treatment with alamandine was well-tolerated, but failed to affect lipid, macrophage, neutrophil or collagen content within carotid and aortic root plaques. Also, treatment with alamandine did not affect Th-cell polarization in lymphoid organs. Conversely, alamandine administration was associated with a reduction in serum levels of neutrophil granule enzymes, such as MMP-9 and MPO as well as MMP-9 content within aortic root plaques. In vitro, preincubation with alamandine dose-dependently abrogated PMA-induced neutrophil degranulation of MMP-9 and MPO. Conclusion These results suggest that treatment with the MrgD agonist alamandine led to a reduced release of neutrophil granule products, potentially interfering with pro-atherosclerotic neutrophil activation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available